<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779177</url>
  </required_header>
  <id_info>
    <org_study_id>ITI-007-020</org_study_id>
    <nct_id>NCT04779177</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder</brief_title>
  <official_title>An Open-label Multiple Oral Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lumateperone in Patients, Ages 13 to 17 Years, Diagnosed With Schizophrenia or Schizoaffective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intra-Cellular Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intra-Cellular Therapies, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study ITI-007-020 is a Phase 1b, multicenter, open-label study to evaluate the safety,&#xD;
      tolerability, and PK of lumateperone as treatment for adolescent patients with schizophrenia&#xD;
      or schizoaffective disorder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Cmax</measure>
    <time_frame>predose and multiple timepoints up to 24 hours postdose on Day 1 and Day 5</time_frame>
    <description>Maximum plasma concentration of lumateperone and metabolites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Tmax</measure>
    <time_frame>predose and multiple timepoints up to 24 hours postdose on Day 1 and Day 5</time_frame>
    <description>Time of maximum concentration of lumateperone and metabolites in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: AUC0-t</measure>
    <time_frame>predose and multiple timepoints up to 24 hours postdose on Day 1 and Day 5</time_frame>
    <description>Area under the plasma concentration time curve from time zero to the last measurable of concentration of lumateperone and metabolites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: AUC0-tau</measure>
    <time_frame>predose and multiple timepoints up to 24 hours postdose on Day 1 and Day 5</time_frame>
    <description>Area under the plasma concentration (lumateperone and metabolites) time curve from time zero to the end of dosing (tau)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: t1/2</measure>
    <time_frame>predose and multiple timepoints up to 24 hours postdose on Day 1 and Day 5</time_frame>
    <description>Terminal elimination half-life of lumateperone and metabolites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: CL/F</measure>
    <time_frame>predose and multiple timepoints up to 24 hours postdose on Day 1 and Day 5</time_frame>
    <description>Apparent oral clearance of lumateperone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with treatment-emergent adverse events</measure>
    <time_frame>up to 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic and diastolic blood pressure</measure>
    <time_frame>up to Day 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ECG QT interval</measure>
    <time_frame>up to Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemoglobin</measure>
    <time_frame>screening, Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in white blood cell count</measure>
    <time_frame>screening, Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in aspartate aminotransferase</measure>
    <time_frame>screening, Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in alanine aminotransferase</measure>
    <time_frame>screening, Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>up to Day 6</time_frame>
    <description>unabbreviated scale title: Abnormal Involuntary Movement Scale. AIMS is a measure of facial and oral movements, extremity movements and trunk movements. Items are rated on a scale from none (0) to severe (4).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Pediatric</condition>
  <arm_group>
    <arm_group_label>Lumateperone 42 mg once daily for 5 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lumateperone 28 mg once daily for 5 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumateperone 42 mg</intervention_name>
    <description>Lumateperone 42 mg, oral administration</description>
    <arm_group_label>Lumateperone 42 mg once daily for 5 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumateperone 28 mg</intervention_name>
    <description>Lumateperone 28 mg, oral administration</description>
    <arm_group_label>Lumateperone 28 mg once daily for 5 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients between 13 and 17 years of age, inclusive&#xD;
&#xD;
          -  Clinical diagnosis of schizophrenia or schizoaffective disorder according to&#xD;
             Diagnostic and Statistical Manual of Mental Disorders (DSM-5)&#xD;
&#xD;
          -  Free from acute exacerbation of their psychosis for at least 3 months prior to&#xD;
             Screening&#xD;
&#xD;
          -  Clinical Global Impression - Severity (CGI-S) score â‰¤ 4&#xD;
&#xD;
          -  Body mass index (BMI) within 2 standard deviations of, age- and gender-specific body&#xD;
             measurements (based on CDC Clinical Growth Chart, 2000)&#xD;
&#xD;
          -  Ability to swallow capsules&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Has a primary psychiatric diagnosis other than schizophrenia or schizoaffective&#xD;
             disorder&#xD;
&#xD;
          -  Reports having experienced suicidal ideation within 6 months prior to Screening, any&#xD;
             suicidal behavior within 2 years prior to Screening based on the Columbia-Suicide&#xD;
             Severity Rating Scale (C-SSRS), and/or the investigator assesses the patient to be a&#xD;
             safety risk to him/herself or others&#xD;
&#xD;
          -  Clinically significant abnormality within 2 years of Screening that in the&#xD;
             Investigator's opinion may place the patient at risk or interfere with study outcome&#xD;
             variables&#xD;
&#xD;
          -  History of a clinically significant cardiac disorder and/or abnormal screening&#xD;
             electrocardiogram (ECG) or a QT interval corrected for heart rate using Fridericia&#xD;
             formula &gt; 450 msec in males or &gt; 470 msec in females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Site</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlanta, Georgia, United States, 30331</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clinical Site</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hollywood, Florida, United States, 33024</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ITI Clinical Trials</last_name>
    <phone>6464409333</phone>
    <email>ITCIClinicalTrials@itci-inc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

